[PDF][PDF] Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification
J Guo, L Si, Y Kong, KT Flaherty, X Xu… - Journal of clinical …, 2011 - researchgate.net
J Guo, L Si, Y Kong, KT Flaherty, X Xu, Y Zhu, CL Corless, L Li, H Li, X Sheng, C Cui, Z Chi…
Journal of clinical oncology, 2011•researchgate.netPhase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic
Melanoma Harboring c-Kit Mutation or Amp Page 1 Phase II, Open-Label, Single-Arm Trial of
Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or
Amplification Jun Guo, Lu Si, Yan Kong, Keith T. Flaherty, Xiaowei Xu, Yanyan Zhu, Christopher
L. Corless, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili
Mao, Xuede Lin, Nan Du, Xiaoshi Zhang, Junling Li, Baocheng Wang, and Shukui Qin Jun Guo …
Melanoma Harboring c-Kit Mutation or Amp Page 1 Phase II, Open-Label, Single-Arm Trial of
Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or
Amplification Jun Guo, Lu Si, Yan Kong, Keith T. Flaherty, Xiaowei Xu, Yanyan Zhu, Christopher
L. Corless, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili
Mao, Xuede Lin, Nan Du, Xiaoshi Zhang, Junling Li, Baocheng Wang, and Shukui Qin Jun Guo …
Purpose
Melanomas harbor aberrations in the c-Kit gene. We tested the efficiency of the tyrosine kinase inhibitor imatinib in selected patients with metastatic melanoma harboring c-Kit mutations or amplifications.
researchgate.net